Orchard Therapeutics PLC
Paul Heal started their work experience in 2000 as a Laboratory Technician at LGC Limited. Paul then moved on to Aptuit in 2001 and eventually transitioned to Covance Laboratories in 2006. At Covance, they worked as a Toxicology Study Director until 2017 when they became the VP of Preclinical Development at Orchard Therapeutics. Throughout their roles, Paul specialized in General Toxicology, Biodistribution Studies, and Viral Vector Testing, maintaining their competence by reviewing literature, attending courses, and networking with others in the field. Paul was also involved in direct liaisons with sponsors on a global scale and responsible for developing study programs tailored to specific regulatory requirements.
Paul Heal completed their Bachelor of Science in Pharmacology at the University of Sunderland from 1992 to 1996. Following this, they pursued a Master of Science in Neuroscience at The University of Manchester from 1997 to 1998.
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.